1. Home
  2. VRDN vs BV Comparison

VRDN vs BV Comparison

Compare VRDN & BV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VRDN
  • BV
  • Stock Information
  • Founded
  • VRDN 2006
  • BV 1939
  • Country
  • VRDN United States
  • BV United States
  • Employees
  • VRDN N/A
  • BV N/A
  • Industry
  • VRDN Medical Specialities
  • BV Business Services
  • Sector
  • VRDN Health Care
  • BV Consumer Discretionary
  • Exchange
  • VRDN Nasdaq
  • BV Nasdaq
  • Market Cap
  • VRDN 1.0B
  • BV 1.4B
  • IPO Year
  • VRDN N/A
  • BV 2018
  • Fundamental
  • Price
  • VRDN $13.92
  • BV $15.63
  • Analyst Decision
  • VRDN Strong Buy
  • BV Buy
  • Analyst Count
  • VRDN 12
  • BV 8
  • Target Price
  • VRDN $38.50
  • BV $17.41
  • AVG Volume (30 Days)
  • VRDN 838.2K
  • BV 706.2K
  • Earning Date
  • VRDN 05-06-2025
  • BV 05-07-2025
  • Dividend Yield
  • VRDN N/A
  • BV N/A
  • EPS Growth
  • VRDN N/A
  • BV N/A
  • EPS
  • VRDN N/A
  • BV N/A
  • Revenue
  • VRDN $302,000.00
  • BV $2,729,300,000.00
  • Revenue This Year
  • VRDN N/A
  • BV $3.32
  • Revenue Next Year
  • VRDN $21,976.14
  • BV $3.15
  • P/E Ratio
  • VRDN N/A
  • BV N/A
  • Revenue Growth
  • VRDN 4.86
  • BV N/A
  • 52 Week Low
  • VRDN $9.90
  • BV $11.81
  • 52 Week High
  • VRDN $27.20
  • BV $18.89
  • Technical
  • Relative Strength Index (RSI)
  • VRDN 55.94
  • BV 52.66
  • Support Level
  • VRDN $13.37
  • BV $15.37
  • Resistance Level
  • VRDN $14.18
  • BV $16.22
  • Average True Range (ATR)
  • VRDN 0.67
  • BV 0.33
  • MACD
  • VRDN 0.14
  • BV -0.16
  • Stochastic Oscillator
  • VRDN 85.65
  • BV 5.90

About VRDN Viridian Therapeutics Inc.

Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly known as VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED).

About BV BrightView Holdings Inc.

BrightView Holdings Inc is a provider of commercial landscaping services in the United States. The company provides commercial landscaping services, landscape maintenance, and enhancements to tree care and landscape development. It operates through two segments namely Maintenance Services, and Development Services. The Maintenance Services are self-performed through a national branch network and are route-based in nature. It includes mowing, gardening, mulching and snow removal, water management etc. And Development Services are comprised of sophisticated design, coordination, and installation of landscapes at recognizable corporate, athletic, and university complexes. The company generates a majority of its revenue from Maintenance Services.

Share on Social Networks: